The Medical Letter on Drugs and Therapeutics
Yosprala - A Combination of Aspirin and Omeprazole
The full article is available to subscribers Subscriber Login   

The FDA has approved Yosprala (Aralez), a fixed-dose combination of delayed-release aspirin and immediate-release omeprazole, for secondary prevention of cardiovascular and cerebrovascular events in patients who are at risk of developing aspirin-associated gastric ulcers (≥55 years old or history of gastric ulcers). Yosprala is the first product to become available in the US that combines aspirin and a proton pump inhibitor (PPI).

SECONDARY PREVENTION — Aspirin irreversibly acetylates cyclooxygenase-1, blocking thromboxane synthesis and inhibiting platelet activation and aggregation for the life of the platelet (up to 10 days). It reduces the incidence of myocardial infarction by 30%, stroke by 20%, and all-cause mortality by 18% when used for secondary prevention of thromboembolic events. The annual risk of serious GI bleeding with aspirin doses ≤325 mg/day is about 0.4%, which is 2.5 times ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Yosprala - A Combination of Aspirin and Omeprazole
Article code: 1513d
 Electronic, downloadable article - $25